Amgen, bone mineral density

Amgen Dismisses Bone Density Concerns Related to Its New Weight-Loss Drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking...
Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, raised safety concerns. The monthly injection stands out as a promising competitor by offering an alternative approach to the weekly treatments from Novo Nordisk and Eli Lilly.
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a recent share price decline. Read more here.
STAT16h
AbbVie’s stumble, Amgen’s tumble and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy Right Now?
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
bovnews9d
Amgen Inc (AMGN) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
On Monday, Amgen Inc (AMGN) stock saw a decline, ending the day at $316.91 which represents a decrease of $-2.31 or -0.72% from the prior close of $319.22. The stock opened at $320.58 and touched a ...
Amgen Inc. stock rises Monday, still underperforms market
Shares of Amgen Inc. AMGN inched 0.06% higher to $317.17 Monday, on what proved to be an all-around positive trading session ...
Yahoo Finance14d
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
Amgen Inc's robust product portfolio and pipeline fortify its market position. Strategic acquisitions like Horizon Therapeutics enhance Amgen's therapeutic reach. Patent litigations and market ...
Seeking Alpha15d
Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
My name is Julianne, and I will be your conference facilitator today for Amgen's Third Quarter 2024 ... launches in multiple markets, including Canada, which launched earlier this year.